Cell Source Financials
| CLCS Stock | USD 0.0002 0.40 99.95% |
Cell |
Understanding current and past Cell Source Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cell Source's financial statements are interrelated, with each one affecting the others. For example, an increase in Cell Source's assets may result in an increase in income on the income statement.
The data published in Cell Source's official financial statements usually reflect Cell Source's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cell Source. For example, before you start analyzing numbers published by Cell accountants, it's critical to develop an understanding of what Cell Source's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cell Source's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cell Source's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cell Source's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cell Source. Please utilize our Beneish M Score to check the likelihood of Cell Source's management manipulating its earnings.
Cell Source Stock Summary
Cell Source competes with HUMANA, Barloworld, Morningstar Unconstrained, High Yield, and Thrivent High. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US15114L1044 |
| Business Address | 57 West 57th |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.cell-source.com |
| Phone | 646 416 7896 |
| Currency | USD - US Dollar |
You should never invest in Cell Source without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cell Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Cell Source's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cell Source Key Financial Ratios
Generally speaking, Cell Source's financial ratios allow both analysts and investors to convert raw data from Cell Source's financial statements into concise, actionable information that can be used to evaluate the performance of Cell Source over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cell Source reports annually and quarterly.| Return On Asset | -3.78 | |||
| Beta | -64.41 |
Cell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cell Source's current stock value. Our valuation model uses many indicators to compare Cell Source value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cell Source competition to find correlations between indicators driving Cell Source's intrinsic value. More Info.Cell Source is rated fourth in return on asset category among related companies. It is the top company in current valuation category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cell Source by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cell Source's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cell Source's earnings, one of the primary drivers of an investment's value.Cell Source Systematic Risk
Cell Source's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cell Source volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Cell Source correlated with the market. If Beta is less than 0 Cell Source generally moves in the opposite direction as compared to the market. If Cell Source Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cell Source is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cell Source is generally in the same direction as the market. If Beta > 1 Cell Source moves generally in the same direction as, but more than the movement of the benchmark.
About Cell Source Financials
What exactly are Cell Source Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cell Source's income statement, its balance sheet, and the statement of cash flows. Potential Cell Source investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cell Source investors may use each financial statement separately, they are all related. The changes in Cell Source's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cell Source's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Cell Source Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Cell Source is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Cell has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Cell Source's financials are consistent with your investment objective using the following steps:- Review Cell Source's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Cell Source's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Cell Source's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Cell Source's stock is overvalued or undervalued.
Cell Source April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cell Source help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cell Source. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cell Source based on widely used predictive technical indicators. In general, we focus on analyzing Cell Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cell Source's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 181.77 | |||
| Value At Risk | (27.91) | |||
| Potential Upside | 25.81 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cell Source. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Cell Source information on this page should be used as a complementary analysis to other Cell Source's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Cell Pink Sheet analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |